Eli Lilly, AstraZeneca Launch Pivotal Clinical Trial For Early Alzheimer’s Disease Drug

Eli Lilly, AstraZeneca Launch Pivotal Clinical Trial For Early Alzheimer’s Disease Drug
Alzheimer’s ResearchEli Lilly and Company and AstraZeneca announced the start of recruitment of patients for the Phase II/III AMARANTH clinical trial of an inhibitor of beta secretes cleaving enzyme (BACE), currently under development as a promising therapy for Alzheimer's disease. Alzheimer’s disease is characterized by two important pathological featu
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *